Croatian startup LyzorTx develops phage therapy model to combat antibiotic resistance

LyzorTx, a startup, is developing a model to identify bacteriophages as an alternative to antibiotics, addressing the growing threat of antimicrobial resistance. The approach is in early development, with clinical efficacy and scalability unproven. This matters as phage therapy could offer a targeted solution where antibiotics fail, but regulatory and production hurdles remain.